Here are five things to know:
1. The permanent implant is designed to react to nervous systems signals by shifting the impulse strength to the damaged areas.
2. This device is considered to be advancing SCS therapy because it can adjust stimulation to the set level the patient desires. With other SCS therapies, patients may experience shocks or intense tingling when they shift positions.
3. Charles Brooker, MD, performed the procedure at Royal North Shore Hospital in Sydney, Australia, inserting the implant in the spinal canal.
4. The patient reported a significant decrease in his chronic back pain following the procedure.
5. Saluda Medical developed the implant. Saluda CEO, John Parker, said the implant will cost $30,000.
More articles on devices:
InVivo’s pilot study expands to 10 spinal cord injury patients — 5 key notes
Stryker, Ziehm Imaging enter into co-marketing agreement: 4 key notes
Amendia, Promimic enter into strategic venture: 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
